---

Interleukin-6 blocker for successful outcome of late-onset rheumatoid oligoarthritis

Full Text PDF

---

Case Report

Author Details : Yuva Vishalini Ravindran, Subramanian Nallasivan

Volume : 3, Issue : 1, Year : 2017

Article Page : 35-36

Suggest article by email

Get Permission

Abstract

Newer cytokine therapies have revolutionised the management of Rheumatoid arthritis. Atypical oligoarthritis can also be a manifestation of RA and CCP antibodies have been proven to be most specific for Rheumatoid. Our patient had 2 years of painful ankle bilaterally and suggested for joint replacement due to osteoarthritis changes. After the diagnosis of RA using Anti-CCP antibodies, we elected to give Tocilizumab(IL 6 Blocker) which had made the patient to walk without wheelchair after 2 years. This suggests early appropriate diagnosis is the key and Biologics- the new Kid in the market- has proven to be effective in early Rheumatoid arthritis.

Keywords: Tocilizumab, Oligoarthitis, IL-6 blocker, Anti-CCP antibodies, Rheumatoid arthritis

How to cite : Ravindran Y V, Nallasivan S, Interleukin-6 blocker for successful outcome of late-onset rheumatoid oligoarthritis. IP Int J Orthop Rheumatol 2017;3(1):35-36

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.